<DOC>
	<DOCNO>NCT01459250</DOCNO>
	<brief_summary>This study ass pharmacokinetics , safety tolerability single dose AGO178C subject mild , moderate , severe renal impairment end-stage renal disease healthy match control subject .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability AGO178C Subjects With Renal Deficiencies Compared With Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<criteria>Mild , moderate , severe renally impaired ESRD patient . Healthy male female subject match renally impaired patient BMI ( ±15 % ) , age ( ± 7 year ) gender ( order ) . Smoking status ( yes ) also use final criterion , deem feasible Investigator . Pregnant nursing ( lactate ) woman Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective contraception study define protocol . Smokers , smoke 10 cigarette per day screen study completion Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion drug , may jeopardize subject case participation study Comedication healthy subject Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>AGO178C ,</keyword>
	<keyword>renal impairment ,</keyword>
	<keyword>ESRD ,</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>